Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$8.73 USD
+0.23 (2.71%)
Updated May 17, 2024 04:00 PM ET
After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
COYA 8.73 +0.23(2.71%)
Will COYA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COYA
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
Here's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
Other News for COYA
Coya Therapeutics GAAP EPS of -$0.35
Coya Therapeutics Reports First Quarter 2024 Financial Results
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
Coya Therapeutics Financial and Operational Results Overview